Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3 years: An open-label extension of randomized clinical trials
JAMA Dermatology 2025;161:56–66 doi: 10.1001/jamadermatol.2024.4688
Armstrong et al. evaluated the long-term safety and efficacy of deucravacitinib in patients with moderate to severe plaque PsO over a three-year period. The study found that exposure-adjusted incidence rates of AEs remained stable or declined over time, with no new safety signals emerging. Clinical response rates, including PASI75/90, were maintained, supporting the drug’s long-term efficacy.
This analysis combined data from the phase 3 POETYK PSO-1 and PSO-2 trials, and a nonrandomised long-term extension trial to assess continuous treatment with deucravacitinib. The study aimed to determine whether deucravacitinib provides sustained efficacy and a stable safety profile over three years, addressing the need for durable therapeutic options in plaque PsO.
Keywords:
